William Blair Investment Management LLC lowered its position in ABIOMED, Inc. (NASDAQ:ABMD) by 13.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 973,794 shares of the medical equipment provider’s stock after selling 147,223 shares during the period. William Blair Investment Management LLC owned approximately 2.22% of ABIOMED worth $139,545,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in the company. Teachers Advisors LLC increased its stake in ABIOMED by 6.5% in the fourth quarter. Teachers Advisors LLC now owns 42,452 shares of the medical equipment provider’s stock worth $4,783,000 after buying an additional 2,608 shares during the last quarter. Creative Planning increased its stake in shares of ABIOMED by 16.4% in the first quarter. Creative Planning now owns 916 shares of the medical equipment provider’s stock valued at $115,000 after buying an additional 129 shares in the last quarter. Bank of Montreal Can increased its stake in shares of ABIOMED by 48.7% in the first quarter. Bank of Montreal Can now owns 19,902 shares of the medical equipment provider’s stock valued at $2,492,000 after buying an additional 6,520 shares in the last quarter. Capstone Asset Management Co. increased its stake in shares of ABIOMED by 2.8% in the first quarter. Capstone Asset Management Co. now owns 6,340 shares of the medical equipment provider’s stock valued at $794,000 after buying an additional 170 shares in the last quarter. Finally, Louisiana State Employees Retirement System increased its stake in shares of ABIOMED by 2.0% in the first quarter. Louisiana State Employees Retirement System now owns 10,200 shares of the medical equipment provider’s stock valued at $1,277,000 after buying an additional 200 shares in the last quarter. Institutional investors and hedge funds own 91.09% of the company’s stock.

Shares of ABIOMED, Inc. (ABMD) opened at 152.14 on Monday. The firm has a market capitalization of $6.68 billion, a P/E ratio of 88.97 and a beta of 0.20. ABIOMED, Inc. has a one year low of $95.14 and a one year high of $157.41. The company has a 50-day moving average price of $147.23 and a 200 day moving average price of $132.32.

ABIOMED (NASDAQ:ABMD) last posted its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.42 by $0.03. ABIOMED had a net margin of 16.13% and a return on equity of 13.03%. The company had revenue of $132.47 million for the quarter, compared to the consensus estimate of $130.83 million. During the same quarter in the previous year, the firm posted $0.29 EPS. The business’s revenue was up 28.6% compared to the same quarter last year. Analysts expect that ABIOMED, Inc. will post $2.24 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/08/21/abiomed-inc-abmd-shares-sold-by-william-blair-investment-management-llc.html.

Several brokerages recently issued reports on ABMD. BidaskClub upgraded ABIOMED from a “hold” rating to a “buy” rating in a report on Thursday, August 10th. William Blair reiterated an “outperform” rating on shares of ABIOMED in a report on Thursday, June 8th. Jefferies Group LLC increased their price target on ABIOMED from $165.00 to $175.00 and gave the company a “buy” rating in a report on Friday, August 4th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $160.00 price target (up from $145.00) on shares of ABIOMED in a report on Thursday, July 27th. Finally, Zacks Investment Research downgraded ABIOMED from a “buy” rating to a “hold” rating in a report on Monday, August 7th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. ABIOMED presently has a consensus rating of “Buy” and an average price target of $158.29.

In other news, COO David M. Weber sold 16,500 shares of the business’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $147.63, for a total transaction of $2,435,895.00. Following the transaction, the chief operating officer now owns 125,122 shares in the company, valued at approximately $18,471,760.86. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Paul Thomas sold 10,000 shares of the business’s stock in a transaction dated Tuesday, August 15th. The stock was sold at an average price of $154.71, for a total transaction of $1,547,100.00. Following the transaction, the director now owns 12,172 shares in the company, valued at approximately $1,883,130.12. The disclosure for this sale can be found here. Insiders own 7.00% of the company’s stock.

ABIOMED Company Profile

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Stock Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related stocks with our FREE daily email newsletter.